Mobile website
Monographic Report
Therapeutic effect of chemokine SLC combined with immune adjuvant CpG-ODN in treatment of implanted mouse melanoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To study the therapeutic effect of secondary lymphoid tissue chemokine (SLC) combined with CpG oligodeoxynucleotide (CpGODN) in treatment of implanted mouse melanoma and the possible mechanism. Methods:SLCFc fusion protein was prepared and its chemotaxis of lymphocytes was detected by chemotaxis assay. Implanted melanoma mouse models were established and randomly divided into 4 groups: control group, SLCFc group, CpGODN group, and SLCFc+CpGODN group. The growth of implanted tumors in each group was observed after treatment. Subtype and infiltration of lymphocytes in implanted tumor tissues were examined by flow cytometry. Results:SLCFc protein was successfully prepared, and it dosedependently attracted lymphocytes (0.03, 0.3, and 3 μg/L). Intratumor injection SLCFc and CpGODN alone or in combination significantly inhibited growth of B16implanted tumors. Tumor size in SLCFc+CpGODN group was significantly smaller than that in control group (P<0.01), and animals in SLCFc+CpGODN group survived longer. Tumorinfiltrated CD4+ T, CD8+ T, and dendritic cells (DCs) in SLCFc+CpGODN group were markedly increased as compared with those in control group (P<0.05), and tumor draining lymph nodes were dramatically enlarged. Conclusion:SLC combined with CpGODN can inhibit the growth of implanted melanoma by attracting CD4+ T and CD8+ T and promoting proliferation of DCs.
Keywords:
Project Supported:
Project surpported by the Scientific Constructive Program of Science and Technology Bureau of Xiamen（No.3502z20089020）
Clc Number:
